Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression

BACKGROUND: Psychotic depression has no Food and Drug Administration–approved treatment. Patients demonstrate significant dysregulation of the hypothalamic-pituitary-adrenal axis providing a biologically targeted treatment opportunity. The purpose of this study was to explore the clinical and biolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Block, Thaddeus, Petrides, Georgios, Kushner, Harvey, Kalin, Ned, Belanoff, Joseph, Schatzberg, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596828/
https://www.ncbi.nlm.nih.gov/pubmed/28708736
http://dx.doi.org/10.1097/JCP.0000000000000744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596828/
https://www.ncbi.nlm.nih.gov/pubmed/28708736
http://dx.doi.org/10.1097/JCP.0000000000000744

Ejemplares similares